Long COVID and the Gastrointestinal System: Emerging Evidence

Article Type
Article
Changed
Thu, 10/05/2023 - 15:45
Display Headline
Long COVID and the Gastrointestinal System: Emerging Evidence
Author(s)
Daniel E. Freedberg, MD, MS, and Lin Chang, MD, AGAF

Click to view more from Gastroenterology Data Trends 2023. 

References
  1. Lutchmansingh DD et al. Semin Respir Crit Care Med. 2023;44(1):130-142. doi:10.1055/s-0042-1759568
  2. Choudhury A et al. Therap Adv Gastroenterol. 2022;15:17562848221118403. doi:10.1177/17562848221118403
  3. Xu E et al. Nat Commun. 2023;14(1):983. doi:10.1038/s41467-023-36223-7
  4. Freedberg DE, Chang L. Curr Opin Gastroenterol. 2022;38(6):555-561. doi:10.1097/MOG.0000000000000876
  5. Blackett JW et al. Gastroenterology. 2022;162(2):648-650.e2. doi:10.1053/j.gastro.2021.10.040
  6. Chey WD et al. Gastroenterology. 2021;160(1):47-62. doi:10.1053/j.gastro.2020.06.099
  7. Líška D et al. Front Public Health. 2022;10:975992. doi:10.3389/fpubh.2022.975992
  8. Moens M et al. Front Public Health. 2022;10:991572. doi:10.3389/fpubh.2022.991572
  9. Cutler DM. The economic cost of long COVID: an update. Scholars at Harvard. Published July 2022. Accessed July 20, 2023. https://scholar.harvard.edu/sites/scholar.harvard.edu/files/cutler/files/long_covid_update_7-22.pdf
  10. National Center for Education Statistics (2023). Public School Expenditures. Condition of Education. US Department of Education, Institute of Education Sciences. Accessed August 4, 2023. https://nces.ed.gov/programs/coe/indicator/cmb
Author and Disclosure Information

Daniel E. Freedberg, MD, MS
Associate Professor of Medicine and Epidemiology
Division of Digestive and Liver Diseases
Mailman School of Public Health, Department of Epidemiology
Columbia University Irving Medical Center
New York, NY

Lin Chang, MD, AGAF
Vice-Chief, Vatche and Tamar Manoukian
Division of Digestive Diseases
Program Director, UCLA GI Fellowship Program
Co-Director, G. Oppenheimer Center for Neurobiology of Stress and Resilience
Director, Clinical Studies and Database Core, Goodman-Luskin Microbiome Center
David Geffen School of Medicine at UCLA
Los Angeles, CA

Publications
GI and Hepatology News
Topics
COVID-19 Updates
Author(s)
Daniel E. Freedberg, MD, MS, and Lin Chang, MD, AGAF
Author(s)
Daniel E. Freedberg, MD, MS, and Lin Chang, MD, AGAF
Author and Disclosure Information

Daniel E. Freedberg, MD, MS
Associate Professor of Medicine and Epidemiology
Division of Digestive and Liver Diseases
Mailman School of Public Health, Department of Epidemiology
Columbia University Irving Medical Center
New York, NY

Lin Chang, MD, AGAF
Vice-Chief, Vatche and Tamar Manoukian
Division of Digestive Diseases
Program Director, UCLA GI Fellowship Program
Co-Director, G. Oppenheimer Center for Neurobiology of Stress and Resilience
Director, Clinical Studies and Database Core, Goodman-Luskin Microbiome Center
David Geffen School of Medicine at UCLA
Los Angeles, CA

Author and Disclosure Information

Daniel E. Freedberg, MD, MS
Associate Professor of Medicine and Epidemiology
Division of Digestive and Liver Diseases
Mailman School of Public Health, Department of Epidemiology
Columbia University Irving Medical Center
New York, NY

Lin Chang, MD, AGAF
Vice-Chief, Vatche and Tamar Manoukian
Division of Digestive Diseases
Program Director, UCLA GI Fellowship Program
Co-Director, G. Oppenheimer Center for Neurobiology of Stress and Resilience
Director, Clinical Studies and Database Core, Goodman-Luskin Microbiome Center
David Geffen School of Medicine at UCLA
Los Angeles, CA

Click to view more from Gastroenterology Data Trends 2023. 

Click to view more from Gastroenterology Data Trends 2023. 

References
  1. Lutchmansingh DD et al. Semin Respir Crit Care Med. 2023;44(1):130-142. doi:10.1055/s-0042-1759568
  2. Choudhury A et al. Therap Adv Gastroenterol. 2022;15:17562848221118403. doi:10.1177/17562848221118403
  3. Xu E et al. Nat Commun. 2023;14(1):983. doi:10.1038/s41467-023-36223-7
  4. Freedberg DE, Chang L. Curr Opin Gastroenterol. 2022;38(6):555-561. doi:10.1097/MOG.0000000000000876
  5. Blackett JW et al. Gastroenterology. 2022;162(2):648-650.e2. doi:10.1053/j.gastro.2021.10.040
  6. Chey WD et al. Gastroenterology. 2021;160(1):47-62. doi:10.1053/j.gastro.2020.06.099
  7. Líška D et al. Front Public Health. 2022;10:975992. doi:10.3389/fpubh.2022.975992
  8. Moens M et al. Front Public Health. 2022;10:991572. doi:10.3389/fpubh.2022.991572
  9. Cutler DM. The economic cost of long COVID: an update. Scholars at Harvard. Published July 2022. Accessed July 20, 2023. https://scholar.harvard.edu/sites/scholar.harvard.edu/files/cutler/files/long_covid_update_7-22.pdf
  10. National Center for Education Statistics (2023). Public School Expenditures. Condition of Education. US Department of Education, Institute of Education Sciences. Accessed August 4, 2023. https://nces.ed.gov/programs/coe/indicator/cmb
References
  1. Lutchmansingh DD et al. Semin Respir Crit Care Med. 2023;44(1):130-142. doi:10.1055/s-0042-1759568
  2. Choudhury A et al. Therap Adv Gastroenterol. 2022;15:17562848221118403. doi:10.1177/17562848221118403
  3. Xu E et al. Nat Commun. 2023;14(1):983. doi:10.1038/s41467-023-36223-7
  4. Freedberg DE, Chang L. Curr Opin Gastroenterol. 2022;38(6):555-561. doi:10.1097/MOG.0000000000000876
  5. Blackett JW et al. Gastroenterology. 2022;162(2):648-650.e2. doi:10.1053/j.gastro.2021.10.040
  6. Chey WD et al. Gastroenterology. 2021;160(1):47-62. doi:10.1053/j.gastro.2020.06.099
  7. Líška D et al. Front Public Health. 2022;10:975992. doi:10.3389/fpubh.2022.975992
  8. Moens M et al. Front Public Health. 2022;10:991572. doi:10.3389/fpubh.2022.991572
  9. Cutler DM. The economic cost of long COVID: an update. Scholars at Harvard. Published July 2022. Accessed July 20, 2023. https://scholar.harvard.edu/sites/scholar.harvard.edu/files/cutler/files/long_covid_update_7-22.pdf
  10. National Center for Education Statistics (2023). Public School Expenditures. Condition of Education. US Department of Education, Institute of Education Sciences. Accessed August 4, 2023. https://nces.ed.gov/programs/coe/indicator/cmb
Publications
GI and Hepatology News
Publications
GI and Hepatology News
Topics
COVID-19 Updates
Article Type
Article
Display Headline
Long COVID and the Gastrointestinal System: Emerging Evidence
Display Headline
Long COVID and the Gastrointestinal System: Emerging Evidence
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Slideshow
Gate On Date
Fri, 09/22/2023 - 16:15
Un-Gate On Date
Fri, 09/22/2023 - 16:15
Use ProPublica
CFC Schedule Remove Status
Fri, 09/22/2023 - 16:15
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

Slideshow below. 

Long COVID is defined by WHO as the development or continuation of new symptoms 3 months after COVID-19 infection, with symptoms lasting for at least 2 months that have no alternative explanation.1,2

Long COVID often includes neuropsychiatric and GI symptoms.1,2 GI manifestations are well known during acute COVID-19, but less understood in long COVID.2 It is estimated that 12% of patients with long COVID have GI symptoms, which may include heartburn, constipation, abdominal pain, nausea and vomiting, and diarrhea.2,3 Patients with long COVID also frequently receive new GI diagnoses, such as functional dyspepsia, IBS, GERD, peptic ulcer disease, and acute pancreatitis.2,3

Proposed causes of GI symptoms post-COVID are varied, including alterations in the gut microbiome and serotonergic signaling and changes downstream from the angiotensin-converting enzyme 2 receptor.2,4 The serotonergic theory links the pathophysiology of long COVID GI symptoms to post-infection IBS and other disorders of gut-brain interaction. Like IBS, long COVID with GI symptoms is frequently associated with non-GI comorbidities, especially mental health comorbidities.5

Currently, no specific treatments are endorsed for long COVID GI symptoms.4 Management focuses on symptom relief and using protocols for the relevant GI disorders; when IBS is present, an integrated and multidisciplinary approach is recommended.4,6 This multifaceted approach, when possible, can be especially helpful in patients with long COVID because of the number of comorbidities and varied symptoms.1,4-6 Long COVID and its multitude of symptoms have a profound negative effect on productivity and quality of life in patients.1,7 Thus, finding efficient treatment approaches is a top priority in navigating the complexity of long COVID and its GI manifestations. 

Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media
Subscribe to Daniel E. Freedberg, MD, MS, and Lin Chang, MD, AGAF